Herbal Teas on Bone Health in an Osteopenic Population

Completed · Not applicable

Conditions studied: Osteopenia

In brief

The project goal is to identify if herbal teas consumed three times per day over a period of three months can improve these markers of bone health as well as improve quality of life (QOL) compared to women taking placebo by increasing osteoblast activity, decreasing osteoclast activity, increasing nocturnal melatonin levels and by decreasing C-reactive protein (CRP) and cortisol levels. Our central hypothesis is that these herbal teas will improve both objective and subjective measures of bone health in a population with osteopenia not taking this regimen by reducing osteoclast activity and increasing osteoblast activity and by reducing stress and anxiety.

Key facts

Study ID

NCT03480126

Run by

Paula Witt-Enderby

People needed

35

Starts

2018-06-01

Expected to finish

2019-08-27

Last updated by the study team

2022-01-11

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• male or female with osteopenia (T-score between -1.0 and -2.5)
• at least 18 years of age
• must be willing to drink tea three times a day for 3 months
• must also be willing to come to the study location on 4 occasions (baseline, end of month 1, end of month 2, and end of month 3),
• must also be willing to come to the study location to provide urinary, salivary and fecal samples on 2 occasions (baseline and at the end of month 3),
• must also be willing to come to the study location to have their blood pressure taken on 4 occasions (baseline, end of month 1, end of month 2, and end of month 3)
• must be willing to come to the study location to complete questionnaires on 2 occasions (baseline and at the end of month 3)
• must be willing to maintain daily diary for 4 months.

You may not qualify if…

• Women or men with osteoporosis
• Women or men with osteopenia due to hyperparathyroidism, multiple myeloma, metastatic bone disease, chronic steroid use
• Women or men who are on any bone therapies (i.e. bisphosphonates, selective estrogen receptor modulators, hormone therapy, teriparatide, and denosumab)
• Women or men with chronic obstructive pulmonary disease (COPD)
• Women or men who smoke

Where it is running

• Duquesne University — Pittsburgh, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.